Corporate | 14 August 2014 07:19
|
Carl Zeiss Meditec AG / Key word(s): 9-month figures/Quarter Results
JENA, 14 August 2014
“Our business continued to show a positive development in the past few months. All three strategic business units (SBUs) contributed to the growth,” commented Dr. Ludwin Monz, Carl Zeiss Meditec AG’s CEO. As in the previous months, unfavorable exchange rates had an exceptionally adverse impact on business. Key figures by business units at a glance Once again, the Surgical Ophthalmology SBU recorded the strongest revenue growth. During the period under review, this SBU’s revenues lifted by around 22 percent year-on-year, with additional support from the acquisition of the Aaren Scientific, which specializes in intraocular lenses, and continued strong demand for innovative intraocular lenses in the premium segment. Even without considering the figures for Aaren Scientific, included for the first time, this business unit recorded substantial double-digit growth. Revenues in the Microsurgery SBU were up slightly year-on-year, with a continued strong adverse impact from exchange rates in the first nine months of the current financial year. After currency adjustments, surgical microscopes and visualization solutions grew by 5.9 percent. The Ophthalmic Systems SBU was able to keep its revenues at almost the previous year’s level. After adjustment for currency translation, this SBU contributed growth of 3.6 percent, with continued strong pressure from the competition in diagnostics and a high level of demand for innovative lasers for refractive vision correction. Revenue by region Taken region by region, revenues in the first nine months of the financial year were highly varied: In the Europe, Middle East and Africa region the individual markets recorded very heterogeneous growth of 7.7 percent with the German market recording slight growth and the Southern European countries continuing to recover, and the Russian market continued to fall after the expiration of state business support programs. The Americas region recorded stable growth on the whole. Revenue in reporting currency fell by 2.9 percent. However, based on constant exchange rates, this equates to slight growth of 0.7 percent. The strongest – currency-adjusted – growth stemmed from the Asia/Pacific (APAC) region and totaled 14.4 percent in the first nine months. Considering the continued unfavorable exchange rates, in particular in this economic region, growth was still 6.8 percent. “Despite the overall difficult market conditions worldwide, we are sticking to our revenue growth target of EUR 910-940 million for the year as a whole. We also still have our sights firmly set on a medium-term target of an EBIT margin of 15 percent. If the unfavorable exchange rates remain, however, we may have to exercise a little more patience before reaching this target,” commented Ludwin Monz. Revenue by strategic business unit
Revenue by region
Press contacts:
Sebastian Frericks, Director Investor Relations, Carl Zeiss Meditec AG
14.08.2014 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de |
| Language: | English | |
| Company: | Carl Zeiss Meditec AG | |
| Göschwitzer Str. 51-52 | ||
| 07745 Jena | ||
| Germany | ||
| Phone: | +49 (0)3641 220-0 | |
| Fax: | +49 (0)3641 220-112 | |
| E-mail: | investors.meditec@zeiss.com,info.meditec@zeiss.com | |
| Internet: | www.meditec.zeiss.de | |
| ISIN: | DE0005313704 | |
| WKN: | 531370 | |
| Listed: | Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr in Berlin, Düsseldorf, Hamburg, Hannover, München, Stuttgart | |
| End of News | DGAP News-Service |
|
|
| 282216 14.08.2014 |